Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

References for PMC Articles for PubMed (Select 18832244)

1.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

2.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.

3.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.

N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975.

4.

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46. doi: 10.1111/j.1365-2125.2008.03134.x.

5.

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37. doi: 10.1111/j.1365-2125.2008.03133.x.

6.

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).

Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N.

Antimicrob Agents Chemother. 2008 Mar;52(3):858-65. Epub 2007 Dec 10.

7.

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.

J Infect Dis. 2007 Jul 15;196(2):304-12. Epub 2007 Jun 5.

8.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups.

Lancet. 2007 Apr 7;369(9568):1169-78. Erratum in: Lancet. 2008 Jan 12;371(9607):116.

PMID:
17416261
9.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.

Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17. Erratum in: Clin Infect Dis. 2007 May 15;44(10):1399.

10.

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ.

Antimicrob Agents Chemother. 2007 Feb;51(2):566-75. Epub 2006 Nov 20.

11.

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N.

J Infect Dis. 2006 Jul 15;194(2):238-46. Epub 2006 Jun 2.

12.

CCR5 deficiency increases risk of symptomatic West Nile virus infection.

Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM.

J Exp Med. 2006 Jan 23;203(1):35-40. Epub 2006 Jan 17.

13.

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.

Westby M, van der Ryst E.

Antivir Chem Chemother. 2005;16(6):339-54. Review.

PMID:
16329283
14.

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.

PMID:
16280694
15.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M.

Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.

16.

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E.

Nat Med. 2005 Nov;11(11):1170-2. Epub 2005 Oct 5.

PMID:
16205738
17.

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.

AIDS. 2005 Mar 25;19(5):487-94.

PMID:
15764854
18.

HIV-1 coreceptor usage, transmission, and disease progression.

Philpott SM.

Curr HIV Res. 2003 Apr;1(2):217-27. Review.

PMID:
15043204
19.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group.

N Engl J Med. 2003 May 29;348(22):2186-95.

20.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group.

N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk